Quick Links


    Print

Px Wire

Px Wire is AVAC's quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Each issue includes news, emerging issues and features upcoming events.



April-June, Volume 7, Number 2

In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people. The pathways for developing these products have key similarities as well as differences—and as the same drugs advance for treatment and PrEP, it will be key to communicate these. We hope this issue of Px Wire is a start.

Advocates who want to learn more can listen to a recent webinar on long-acting injectables.

This quarter’s issue also explores progress in implementing oral PrEP. It's been nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP. In that time we've seen an increasing number of people begin to view the strategy as an important niche intervention that could save lives and should be promoted more widely. For more information on PrEP, visit www.prepwatch.org.

View the latest issue: (PDF, HTML).


Download graphics from the latest issue of Px Wire:

- Long-Acting Products in Development for Prevention and/or Treatment of HIV (PDF), (JPEG)
- Introduction to Long-Acting Injectables (PDF), (JPEG)







     


Px Wire Archive: View Px Wire issues starting from January 2008

AVAC: Global Advocacy for HIV Prevention
101 West 23rd Street   ·  New York, NY  
+1 212.796.6423 (main)   ·  avac@avac.org
Copyright 2014, All rights reserved.
Design by Lomangino Studio | Powered by Orchid Suites Orchid ver. 4.7.6.